#USA #Cambridge #NeuroSense #Alzheimer’s Disease #Steven Arnold

NeuroSense Therapeutics Welcomes Prof. Steven Arnold

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-stage biotechnology company dedicated to developing novel therapies for severe neurodegenerative diseases, has made headlines once again. The company recently announced that it has enlisted the expertise of Prof. Steven E. Arnold, a distinguished researcher renowned for his contributions to Alzheimer's disease studies, as a member of its Scientific Advisory Board. This strategic addition is poised to bolster NeuroSense's ongoing initiatives focused on Alzheimer's and amyotrophic lateral sclerosis (ALS).

Prof. Arnold, who serves as a Professor of Neurology at Harvard Medical School, brings with him a wealth of experience in biomarkers, clinical development, and translational neuroscience. His involvement is expected to significantly enhance NeuroSense's scientific leadership as the company advances its drug candidate, PrimeC, through clinical trials aimed at addressing both Alzheimer's and ALS.

Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense, expressed enthusiasm over Prof. Arnold’s joining, emphasizing that his extensive background in biomarker-driven clinical development remains essential for the company’s objectives. “Prof. Arnold's depth of experience aligns closely with how we are advancing our programs,” stated Ben-Noon. “His perspective will be invaluable as we continue to execute our plans across both Alzheimer's disease and ALS.”

In a statement, Prof. Arnold acknowledged the multi-target approach of NeuroSense's PrimeC, which he believes is crucial for addressing the complex mechanisms underlying Alzheimer's disease. “I look forward to reviewing the forthcoming clinical and biomarker data and to contributing to the program as it moves forward,” he noted.

NeuroSense recently completed its proof-of-concept study targeting Alzheimer's disease, known as the RoAD study, with preliminary results indicating a favorable safety and tolerability profile. The company anticipates clinical and biomarker outcomes from this study to be available in the first quarter of 2026. As NeuroSense continues to gather valuable data from its ongoing research, this new collaboration with Prof. Arnold marks an important step in its journey toward offering more effective treatments for all those affected by this debilitating condition.

Understanding Alzheimer’s Disease

Alzheimer's disease is recognized as one of the leading causes of dementia worldwide, impacting over 30 million individuals globally. This progressive neurodegenerative disorder is characterized by memory loss, cognitive decline, and significant changes in behavior, and, unfortunately, there are currently no effective cures available. The existing treatments provide minimal symptomatic relief, paving the way for an urgent demand for innovative disease-modifying therapies that can slow or halt its progression.

The complexity of Alzheimer's necessitates a multi-faceted approach to treatment. NeuroSense's PrimeC is designed to engage various biological pathways that play essential roles in Alzheimer's pathology, aiming to offer meaningful therapeutic advancements not only for patients but also for their families.

About PrimeC

PrimeC is the lead drug candidate for NeuroSense and is an innovative extended-release oral formulation made up of a well-studied combination of two FDA-approved drugs: ciprofloxacin and celecoxib. This unique formulation is strategically developed to synergistically act on multiple mechanisms implicated in neuron degeneration, inflammation, iron accumulation, and impaired RNA regulation. By targeting these pathways, PrimeC seeks to potentially inhibit the progression of neurodegenerative diseases, including ALS and Alzheimer's.

About NeuroSense

NeuroSense Therapeutics Ltd. stands at the forefront of clinical-stage biotechnology dedicated to unearthing new solutions for those battling debilitating neurodegenerative diseases. The company understands that conditions like Alzheimer's, ALS, and Parkinson’s present some of the most pressing unmet medical needs of our time, with few effective therapeutic options available. By focusing on comprehensive therapeutic strategies targeting several interconnected pathways, NeuroSense is determined to pave the way for advancements in treatment.